Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Tap, W. D.,Papai, Z.,Van Tine, B. A.,Attia, S.,Ganjoo, K. N.,Jones, R. L.,Schuetze, S.,Reed, D.,Chawla, S. P.,Riedel, R. F.,Krarup-Hansen, A.,Toulmonde, M.,Ray-Coquard...; Lancet Oncol.. 2017 Jun 28.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis, M. J.,Suman, V. J.,Hoog, J.,Goncalves, R.,Sanati, S.,Creighton, C. J.,DeSchryver, K.,Crouch, E.,Brink, A.,Watson, M.,Luo, J.,Tao, Y.,Barnes, M.,Dowsett, M.,Budd...; J. Clin. Oncol.. 2017 Jan 04.

Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.

Tiwari SR, Mishra P, Raska P, Calhoun B, Abraham J, Moore H, Budd GT, Fanning A, Valente S, Stewart R, Grobmyer SR, Montero AJ; Breast Cancer Res. Treat.. 2016-07-01.